ASRS 2021: A Focus on Wet Age-Related Macular Degeneration eBOOK
Focus on Macular Degenerationv2.indd
ASRS 2021
Real-World & Clinical Trial Patients & Their Outcomes Differ
Most patients with neurovascular age-related macular degeneration (nAMD) would not qualify for the trials that inform currents standards of care, according to a study presented at the 39th Annual Scientific Meeting of ASRS 2021...
Only One-Third of Medicare Patients With nAMB Stay With Anti-VEGF Treatment
Only one-third of Medicare beneficiaries with neovascular age-related macular degeneration (nAMB) were “persistent” with anti-VEGF monotherapy treatment each year, according to a study presented at the 39th Annual Scientific...
High Travel Burden Linked With Under-Representation in nAMD Trials
Geographic disparities in access to clinical trial sites exist for neovascular age-related macular degeneration (nAMD) in the United States, according to a study presented at the 38th Annual Scientific Meeting of the American...
ASRS: Medicare Survey Analysis Of Patients With Neovascular Age-Related Macular Degeneration
Only a third of Medicare beneficiaries were persistent with anti-VEGF monotherapy each year. Overall, two-thirds of patients treated with anti-VEGF at baseline (BL) reported similar or better visual function after 2 years....
ASRS: Geographic Access Disparities of Clinical Trials in nAMD
There are geographic disparities in access to clinical trial sites for neovascular age-related macular degeneration (nAMD) in the US. While proximity to urban centers is beneficial for efficiency and retention of subjects, the...
ASRS: Fluid Quantification From Daily Self-imaging With Home OCT in NV-AMD
Analysis suggests that daily self-imaging generated images of satisfactory quality for human grading and automated analysis of fluid volume over time permitting a novel paradigm of monitoring. Home OCT may allow personalized...
ASRS: Apples and Oranges: Comparing “Real-World” And Clinical Trial Outcomes
The average patient with neovascular age-related macular degeneration (nvAMD) would not qualify for the trials that determine current standards of care. Clinical trial methodology could be to blame for real-world patients having...
ASRS 2021: Encore Presentation, Intravitreal Gene Therapy for DME
Data from the INFINITY clinical trial of ADVM-022 in patients with diabetic macular edema (DME) during the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting and will be presented an encore presentation...
ASRS 2021: Oral Retina Drug Shows Favorable Safety, Tolerability
Positive phase 1 and 2 findings support an ongoing efficacy assessment of the Ref-1 inhibitor for diabetic retinopathy and diabetic macular edema. Investigative oral drug APX3330 has been associated with generally favorable...
ASRS 2021: Single Gene Therapy Injection for Retinal Degenerative Disease
Findings from a Phase 1/2a clinical trial of its Multi-Characteristic Opsin (MCO) gene therapy for people blinded by retinitis pigmentosa (RP) were highlighted in two presentations during the 2021 Annual Meeting of the American...
